BOWIE, Md., May 1, 2013 /PRNewswire/ -- Inovalon, Inc., a leading provider of data-driven healthcare solutions, today announced two comparative effectiveness research studies to be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting May 18–22 in New Orleans, La. The studies were supported by data from Inovalon's Medical Outcomes Research for Effectiveness and Economics (MORE2) Registry®.
The Inovalon Statistical Research Team will be presenting the following abstracts:
1. Comparative Risks of Severe Cutaneous Reactions, Aseptic Meningitis, and Organ Dysfunction Associated with Antiepileptic Drugs. The objective was to evaluate the relative likelihood of severe cutaneous reactions (Steven-Johnson Syndrome, toxic epidermal necrolysis), aseptic meningitis, and organ dysfunction (pancreatitis, hepatotoxicity) associated with antiepileptic drugs (AEDS) in children (aged 2–18 years) as compared to adults (aged 19+) with epilepsy. This study provides new information about the comparative risks of AEDS that can be used to guide optimal prescribing practices for patients with epilepsy.
2. Comparative Effectiveness of Antipsychotics and Valproate Versus Antipsychotic use Alone on the Risk of Long-Term Clinical Outcomes and Mortality in the Elderly Populations with Schizophrenia. The objective was to evaluate the relative likelihood of cardiac events, pancreatitis, pneumonia, and death associated with use of valproate as an adjunct "off label" therapy to antipsychotics in the elderly population with schizophrenia. This study provides new evidence to inform prescribing practices in elderly patients with schizophrenia. The increased risk of stroke must be weighed against any incremental benefit to the patient that the addition of valproate may provide.
"Inovalon is using high level analytic tools to unleash the power of big data to better understand causes and outcomes related to various treatment protocols and health services across the increasingly complex universe of conditions, diseases, and treatment options," said Jon Bumbaugh, Senior Director of Research, Development, and Analytics at Inovalon. "The goal is to help answer the question: 'What works best under what conditions for what patients?' This research will support development of evidence based guidelines and practices better tailored to individual patient characteristics to support optimal treatment plans and help clinicians both predict and prevent related adverse outcomes."
Inovalon's Health Services Researchers, co-authors of the research include: Alexis Parente, M.A.; Christie Teigland, Ph.D.; Barton Jones, M.S.; Sandhya Mehta, Ph.D.; Ping Chen, M.S.; Xiaoqin Yang, Ph.D.; and John Scoggins, Ph.D., M.S.
The presentations will be held during Session I on Monday, May 20, starting at 8:30 am.
About Inovalon, Inc.
Inovalon, Inc. is a leading technology-enabled healthcare solutions provider focused on the importance of healthcare data and its ability to drive dramatic, objective improvement in clinical and quality outcomes, care management and financial performance throughout the healthcare community. Proprietary healthcare datasets, aggregation and analysis capabilities, combined with a national infrastructure of leading-edge technology, clinical prowess and deep human resources, empower Inovalon's advanced generation of healthcare assessment and improvement through highly informed solutions. Driven by data, Inovalon uniquely identifies gaps in care, quality, data integrity, and financial performance – while also bringing to bear the resources to resolve them. This differentiating combination provides a powerful capability suite, touching more than 540,000 physicians, 220,000 clinical facilities, and more than 120 million Americans, driving high‐value impact, improving the quality and economics for health plans, hospitals, physicians, patients, and researchers. Please visit www.inovalon.com for more information.
SOURCE Inovalon, Inc.